
|Articles|February 1, 2005
Iris pigmentation changes monitored with glaucoma therapy
Uppsala, Sweden—Adjunctive latanoprost (Xalatan, Pfizer) therapy for open-angle glaucoma is safe and effective, based on the results of a 5-year assessment of the drug. The mean decrease in IOP was 25% of the baseline IOP and this was sustained without any treatment change in 70% of eyes.
Advertisement
Newsletter
Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Ophthalmology Times - Clinical Insights for Eye Specialists
1
AAO 2025: Advancements in laser refractive surgery
2
Kodiak Sciences releases follow-up, 20-week data from APEX study
3
From then to next: Five decades of transformation in ophthalmology
4
Opus Genetics has Type B RMAT meeting with FDA for its gene therapy candidate, OPGx-LCA5
5


















































.png)


